Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop IPI-NIVO
2022-002673-28Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Ongoing response rate at 12 months. Started Oct 2022; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-002673-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002673-28.